Real-World PFS for ALK TKIs in ALK+ NSCLC Patients

Mohammad Jahanzeb, et al., The Oncologist

Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.

 

Image
Real-World PFS for ALK TKIs in ALK+ NSCLC Patients